IP Library Granted Patent US 7,432,093
Granted Patent B2
US 7,432,093 · App. 11/045,540 · Granted Oct 7, 2008

Soluble, functional apoptotic protease-activating factor 1 fragments

Assignee: The Trustees of Princeton University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,432,093
App. No.
11/045,540
Granted
Oct 7, 2008
Kind
B2
Abstract

The structure of a soluble, functional fragment of human Apaf-1 protein having ADP bound thereto is disclosed. The invention includes such soluble, functional fragments of human Apaf-1 and other metazoan Apaf-1 homologs. Also included in the invention are methods of making such fragments and methods of using them, for example in screening methods to identify adenine nucleotide analogs and other compounds useful for alleviating or preventing disease conditions associated with inappropriate regulation of apoptosis.

Claims (15)

1. An isolated soluble, functional fragment of a metazoan apoptotic protease-activating factor 1 (Apaf-1), the fragment having an amino acid sequence that comprises residues 94-349 of SEQ ID NO: 1 and lacking a portion of the WD40 repeat domain of the factor, wherein the native full-length amino acid sequence of the factor comprises SEQ ID NO: 1.

2. The fragment of claim 1 , wherein the factor is Apaf-1 of a chordate.

3. The fragment of claim 1 , wherein the factor is human Apaf-1.

4. The fragment of claim 1 , wherein the cysteine residue present at residue 115 of SEQ ID NO: 1 is altered to be a serine residue.

5. The fragment of claim 1 , wherein the lysine residue present at residue 160 of SEQ ID NO: 1 is altered to be an arginine residue.

6. The fragment of claim 1 , having an amino acid sequence that comprises residues 1-349 of SEQ ID NO: 1.

7. The fragment of claim 1 , having an amino acid sequence that comprises residues 94-589 of SEQ ID NO: 1.

8. The fragment of claim 7 , wherein the cysteine residue present at residue 568 of SEQ ID NO: 1 is altered to be a serine residue.

9. The fragment of claim 1 , having an amino acid sequence that comprises residues 1-591 of SEQ ID NO: 1.

10. The fragment of claim 1 , comprising most of the helical domain I of the factor.

11. The fragment of claim 1 , further comprising the CARD domain of the factor.

12. The fragment of claim 1 , further comprising the winged-helix domain of the factor.

13. The fragment of claim 12 , further comprising at least most of the helical domain II of the factor.

14. The fragment of claim 1 , comprising the entire helical domain I of the factor and further comprising the CARD domain, the winged-helix domain, and most of the helical domain II of the factor.

15. The fragment of claim 14 , comprising the entire helical domain II and at least a portion of the WD40 repeat domain of the factor.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT DOCUMENT PREVIOUSLY RECORDED ON REEL 037383 FRAME 0788. ASSIGNOR(S) HEREBY CONFIRMS THE EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE. Recorded Jan 7, 2016
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 037452/0309 →
CONFIRMATORY LICENSE Recorded Dec 30, 2015
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 037383/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2005
From: SHI, YIGONG
To: TRUSTEES OF PRINCETON UNIVERSITY, THE
Reel/Frame 016479/0829 →
Continuity (2)
Provisional Application 6062800000 · Nov 15, 2004
Related Publication 20060106200A1 · May 18, 2006